Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDOVA
2024-515572-13-00Phase 2Completed
- Sponsor
- Kancera
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of rugocrixan in ovarian cancer, epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and 1 more, sponsored by Kancera. Primary endpoints: Occurrence of adverse events, serious adverse events, and dose limiting toxicities, Safety parameters (AEs, vital signs, ECG, laboratory tests, urinalysis) and 1 more. Started Oct 2024; status: completed.
02
Drugs
rugocrixan
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-515572-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515572-13-00.